Conditions: HIV Infections Heart Disease
Keywords: HIV Heart Disease Bone Density
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 147
Healthy volunteers: no

Brief summary:
The hypothesis of this study is that 96 weeks of Rosuvastatin will be safe and effective in decreasing cardiovascular risk and bone loss in the HIV+ population.

Detailed description:
While the use of antiretroviral therapy (ART) in recent years has had an impressive impact on mortality and disease progression in HIV-infected patients, nevertheless, cardiovascular disease is a major concern impacting morbidity and mortality in this population.

This study will assess if a potent statin, rosuvastatin, could improve endothelial dysfunction, slow carotid intima media thickness (IMT) progression and bone loss, and decrease inflammation and oxidative stress in HIV-infected ART-treated subjects with good HIV virologic control. The investigators will also see if rosuvastatin will induce beneficial changes in the prevalence of metabolic syndrome and lipid metabolism as well as improve bone turnover markers.

Arms:
arm 1: Participants will take Rosuvastatin 10 mg. daily for 96 weeks arm 2: Participants will take a placebo that appears on the exterior to be the same as active drug. They will take one capsule daily.

Interventions: intervention 1: Rosuvastatin 10 mg. daily for 96 weeks intervention 2: Placebo
Intervention descriptions: intervention 1: Participants will take Rosuvastatin 10 mg. daily for 96 weeks. intervention 2: participants will take a sugar pill daily for 96 weeks

Protocol document: